ENVERIC BIOSCIENCES, INC. Adjustment To Additional Paid In Capital Convertible Debt Instrument Issued At Substantial Premium
ENVERIC BIOSCIENCES, INC. (ENVB) reported Adjustment To Additional Paid In Capital Convertible Debt Instrument Issued At Substantial Premium of $298.71 thousand for the 3-month period ending 2021-03-31, per its 10-Q filed 2022-11-14.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentToAdditionalPaidInCapitalConvertibleDebtInstrumentIssuedAtSubstantialPremium · last filed 2022-11-14
- ENVERIC BIOSCIENCES, INC. adjustment to additional paid in capital convertible debt instrument issued at substantial premium for the quarter ending 2021-03-31 was $298.71K.
| Period end | Adjustment To Additional Paid In Capital Convertible Debt Instrument Issued At Substantial Premium 3 month |
|---|---|
| 2021-03-31 | $298.71K 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |